On Monday, Biomarin Pharmaceutical Inc (BMRN) stock saw a decline, ending the day at $66.01 which represents a decrease of $-0.59 or -0.89% from the prior close of $66.6. The stock opened at $66.24 ...

BioMarin Pharmaceutical (BMRN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by ...

The biotech beat Wall Street’s third-quarter revenue forecast by 6%, driven by increased uptake of its achondroplasia drug ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great ...

BioMarin Pharmaceutical ( BMRN -4.44%), a leader in treatments for rare genetic disorders, released its Q3 2024 earnings on ...

BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong ...

UBS raised the firm’s price target on BioMarin (BMRN) to $106 from $104 and keeps a Buy rating on the shares. BioMarin ...

We recently published a list of 10 Best Falling Stocks To Buy According to Hedge Funds. In this article, we are going to take ...

In a report released yesterday, Phil Nadeau from TD Cowen maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), ...

A total of 27 analyst ratings have been received for Biomarin Pharmaceutical, with the consensus rating being Outperform. The average one-year price target stands at $100.85, suggesting a potential 44 ...